Callio Therapeutics

📍 Seattle, United States🗓 Founded 2025👥 19 employees💰 Last funded Mar 2025
Biotechnology Research🌐 calliotx.com
Website LinkedIn
Callio Therapeutics is pioneering the next generation of antibody-drug conjugates with a pipeline of dual-payload ADCs designed to overcome treatment resistance and drive deeper, more durable responses. While first-generation ADCs have transformed cancer treatment, most patients ultimately progress and have urgent need for better therapies. Powered by highly adaptable dual-payload technology, backed by top life science investors, and led by an experienced team with a track record of success, Callio Therapeutics is built to deliver better outcomes for patients.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2025
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Callio Therapeutics?
Callio Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Callio Therapeutics last raise funding?
The most recent investment in Callio Therapeutics recorded on gritt.io was in March 2025.
When was Callio Therapeutics founded?
Callio Therapeutics was founded in 2025.
What industry is Callio Therapeutics in?
Callio Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Callio Therapeutics based?
Callio Therapeutics is headquartered in Seattle, United States.